Appearing in Neuroscience Letters is an article (co-authored by Drs. Daniel Paris and Michael Mullan) announcing the discovery of a new class of drugs that lower the production of the main pathological proteins (beta amyloid plaques) causing Alzheimer’s disease.
According to Dr. Michael Mullan, Director of the Roskamp Institute:
"When B-amyloid builds up in humans, patients develop Alzheimer's Disease. By stopping its production we can potentially stop the disease.
We have found a whole family of drugs that can stop the production of B-amyloid, giving many companies working on NF-kB inhibitors the opportunity to test these types of drugs in Alzheimer's."
A protein occurring in all cells of the body, NF-kB inhibitors are being developed widely in the pharmaceutical industry mainly for its use in inflammatory like arthritis.
Now, its potential is being tested for the treatment of Alzheimer’s disease and has been found to control the production of beta amyloid.
Read the full report. Copy of article here (a pdf file).
[Photo Credit: PDR Health]
Comment Preview